Results 21 to 30 of about 4,718 (156)

Genetic inactivation of Semaphorin 3C protects mice from acute kidney injury [PDF]

Kidney International, 2022
International audienceTo guide the development of therapeutic interventions for acute kidney injury, elucidating the deleterious pathways of this global health problem is highly warranted.
Dussaule, JC, Xu-Dubois, YC, Scambler, Peter, ´lie Calmont, Ame, Scambler, PJ, Xu-Dubois, Yi-Chun, Chadjichristos, Christos, Fre `re, Perrine, Frère, Perrine, Placier, Sandrine, Kormann, R, Lannoy, Morgane, Cai, A, Placier, S, Dussaule, Jean-Claude, Genest, M, Lannoy, M, Surin, B, Chatziantoniou, Christos, Calmont, A, Chatziantoniou, C, Vandermeersch, Sophie, Chadjichristos, CE, Kormann, Raphael, Ye, G, Surin, Brigitte, Vandermeersch, S, Cai, Anxiang, Calmont, Amélie, Ye, Guanyu, Genest, Magali, Frère, P   +31 more
core   +4 more sources

Do Semaphorins Play a Role in Development of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease?

Biomedicines, 2022
Nonalcoholic fatty liver disease (NAFLD) is associated with systemic changes in immune response linked with chronic low-grade inflammation and disease progression.
Lara Šamadan, Neven Papić, Maja Mijić, Ivana Knežević Štromar, Slavko Gašparov, Adriana Vince   +5 more
doaj   +2 more sources

Semaphorin 3C is not required for the establishment and target specificity of the GABAergic septohippocampal pathway in vitro

European Journal of Neuroscience, 2011
International audienceThe septohippocampal (SH) pathway comprises cholinergic and GABAergic fibers. Whereas the former establish synaptic contacts with all types of hippocampal neurons, the latter form complex baskets specifically on interneurons.
Pascual, Marta, Chauvet, Sophie, Rubio, Sara, Fanny Mann, Sara E. Rubio, Sophie Chauvet, Eduardo Soriano, Mann, Fanny, Soriano, Eduardo, Albert Martínez, Marta Pascual, Martínez, Albert   +11 more
core   +4 more sources

An Immune-privileged niche mediates immunotherapy resistance in esophageal carcinoma [PDF]

Journal for ImmunoTherapy of Cancer
Background Neoadjuvant immunotherapy has reshaped the treatment paradigm for esophageal squamous cell carcinoma (ESCC), yet mechanisms of resistance in non-responders remain poorly understood.
Min Wang, Li Zhang, Qilong Wang, Li Wan, Xinyi Chen, Fei Xie, Boye Li, Tianyun Ma, Haotian Ge, Zixuan Xiao, Lingda Meng, Kunxin Xie   +11 more
doaj   +2 more sources

The relationship between semaphorin 3C and microvessel density in the progression of breast and oral neoplasia

Experimental and Molecular Pathology, 2015
This study aimed to identify the expression of semaphorin 3C (SEMA3C) in the normal-metastatic spectrum of breast and oral cancers, and correlate expression with microvessel density (MVD, CD31), a surrogate marker of angiogenesis.
Keith Hunter (8030276), Carolyn A Staton (16225091), Malcolm Reed (4465876), Nicola J Brown (16225088), Zachary Cole-Healy (16225082), Patricia Vergani (16225085)   +5 more
core   +3 more sources

Semaphorin 3C preserves survival and induces neuritogenesis of cerebellar granule neurons in culture

Journal of Neurochemistry, 2003
Semaphorins (sema) constitute a family of molecules sharing a common extracellular domain (semaphorin domain). This family includes several types of secreted and membrane-associated molecules that are grouped into eight subclasses (subclasses 1–7 and ...
Martin-Aparicio, E, McMahon, Stephen B., Moreno-Flores, María Teresa, McMahon, S, Diaz-Nido, J, Ávila, Jesús, Wandosell, F, Martin-Bermejo, M J, Martín-Aparicio, Ester, Moreno-Flores, M T, Agudo, M, Agudo, Marta, Wandosell, Francisco, Avila, J, Díaz-Nido, Javier, Martín-Bermejo, María Jesús   +15 more
core   +5 more sources

Abstract 2256: Semaphorin 3C has a possibility of a new prognostic marker in colorectal cancer

Cancer Research, 2017
Background: Generally, Semaphorins are secretary or transmembrane-bound molecules that act as axon guidance cues in the nervous system. Recent research showed increased expression of semaphorin 3C correlates with cancers that possess higher invasive and ...
Hirokazu Matsuzawa, Makoto Takahashi, Masaya Kawai, Shinya Munakata, Kota Amemiya, Kumpei Honjo, Yu Okazawa, Kiichi Sugimoto, Kazuhiro Sakamoto, Shunsuke Motegi, Shun Ishiyama, Yurika Makino, Atsushi Ochiai, Michitoshi Goto, Hiromitsu Komiyama, Motohiro Kojima, Yuki Tsuchiya, Shingo Kawano, Rina Takahashi, Ryosuke Ichikawa, Toshiaki Hagiwara, Kazumasa Kure, Hirohiko Kamiyama, Kosuke Mizukoshi, Ryoichi Tsukamoto, Shingo Ito, Yuichi Tomiki, Koichiro Niwa, Yutaka Kojima, Hisashi Ro, Atsushi Okuzawa   +30 more
core   +2 more sources

Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells. [PDF]

Endocr Relat Cancer, 2023
Intratumoral androgen biosynthesis contributes to castration-resistant prostate cancer progression in patients treated with androgen deprivation therapy. The molecular mechanisms by which castration-resistant prostate cancer acquires the capacity for androgen biosynthesis to bypass androgen deprivation therapy are not entirely known. Here, we show that
Yenki P, Bhasin S, Liu L, Nabavi N, Cheng CW, Tam KJ, Peacock JW, Adomat HH, Tombe T, Fazli L, Ivanova L, Dusek C, Khosravi S, Guns EST, Wang Y, Buttyan R, Gleave ME, Ong CJ.   +17 more
europepmc   +3 more sources

Abstract 1834: Semaphorin 3C is an androgen receptor-regulated gene

Cancer Research, 2016
Abstract Prostate cancer (PCa) is the second leading cause of cancer-related deaths in North America. The androgen receptor (AR) is a member of the nuclear receptor superfamily of transcription factors and is heavily implicated in PCa progression.
Paul S. Rennie, Artem Cherkasov, Michael Hsing, Yuzhuo Wang, Kush Dalal, James W. Peacock, Yan Ting Chiang, Kevin J. Tam, Martin E. Gleave, Aishwariya Sharma, Chi Wing Cheng, Christopher J. Ong   +11 more
core   +2 more sources

Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. [PDF]

J Endocr Soc, 2018
Despite the amenability of early-stage prostate cancer to surgery and radiation therapy, locally advanced and metastatic prostate cancer is clinically problematic. Chemical castration is often used as a first-line therapy for advanced disease, but progression to the castration-resistant prostate cancer phase occurs with dependable frequency, largely ...
Lee CCW, Munuganti RSN, Peacock JW, Dalal K, Jiao IZF, Shepherd A, Liu L, Tam KJ, Sedgwick CG, Bhasin S, Lee KCK, Gooding L, Vanderkruk B, Tombe T, Gong Y, Gleave ME, Cherkasov A, Ong CJ.   +17 more
europepmc   +4 more sources